© JAN 2026 | IRE Journals | Volume 9 Issue 7 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I7-1714043

The Mechanism of Action and Synergy of CJC-1295 and Ipamorelin Peptide Blend

BENJAMIN PEREZ BS MS
Independent Researcher

Abstract- ***Growth hormone (GH) is an essential hormone in metabolism, reparation of tissues, body composition and recovery processes. Instead of replacing exogenous hormones, peptide-based strategies focus on triggering endogenous GH secretion by the targeting of certain control mechanisms of the hypothalamic-pituitary axis. One of these methods is the combination of CJC-1295 and Ipamorelin where such an option is complementary, and the effects are combined. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, which stimulates the pituitary gland long-term and facilitates the long-term GH signaling. Ipamorelin, on the contrary, is a selective ghrelin receptor agonist, which stimulates fast and sustained pulses of GH release and has limited relationship with stress-related hormones. Combination of these peptides results in activation of different but overlapping pathways which are closer to natural GH secretion patterns in the body. This is a two-way stimulation that permits a baseline stimulation and pulsatile release to minimize the use of a single signaling mechanism and increase the overall hormonal efficiency. The synergistic effect of CJC-1295 and Ipamorelin is a well-organized platform to learn more about the growth hormone modulation in studies and education. This paper will look at the action of each peptide individually, clarify the physiological reason behind the combination of the action, and will describe the rationale behind blending of peptides in an attempt to have balance and controlled GH stimulation. Concentrating on the mechanism and not only on the outcome, the discussion dwells on the scientific principles of this combination of peptides.***

Keywords: CJC-1295, Ipamorelin, Growth Hormone Modulation, Peptide Synergy, Dual-Pathway Stimulation

I. INTRODUCTION

The use of peptides has become an important instrument in current research activities in biomedical and physiological research as it is able to engage in very specific biological pathways. Peptides, in contrast to larger pharmaceutical agents, are modeled to reflect or affect naturally occurring signaling molecules in the body, and thus can be used to modulate complex systems with a great deal of precision. It is this particularity that has made peptides a subject of increased interest in the research environment that is concerned with hormonal regulation, metabolic balance and tissue-level signaling. The peptide-based approaches to the examination of the different hormonal systems include the growth hormone regulation, due to the central position that it plays in the process of sustaining the physiological functions of the system. Growth hormone plays an extensive part in various biological processes, such as metabolic effectiveness, tissue continuity, cell recovery, and signaling in recovery. Its secretion is closely controlled by the hypothalamic-pituitary axis and it is based on a ratio of stimulatory and inhibitory messages instead of constant secretion. Due to this complexity direct hormone supplementation has been considered blunt and is a method that circumvents endogenous control. By comparison, peptides meant to modulate growth hormone pathways are intended to interact with the already-existing receptors and messengers on which hormones release depends. This difference forms the basis of the rationale of peptide blends that rather concentrate on regulation and not replacement.

It is against this background of specific hormone signaling that the combination of CJC-1295 and Ipamorelin was developed. These peptides were not independent agents with overlapping roles but rather they were matched to complete each other in the growth hormone regulatory system. All the peptides are concerned with various parts of the growth hormone stimulation, and researchers can use this to gain a more physiologically balanced and aligned perspective of hormone regulation. The combination is not supposed to boost one signal above the rest, but rather it is meant to assist orchestrated signalings that portray the natural regulation patterns of the body. CJC-1295 and Ipamorelin blend is a strategic formulation and not necessarily a mere mixture of two peptides that play different roles in regulating growth

hormone. This blend aims at the purpose to have a structured platform on which growth hormone dynamics can be studied with several regulatory inputs. This method recognizes that sustained signaling and episodic stimulation is the condition of growth hormone release that is not controlled by any single stimulus. Consequently, the blend is poised as a scientific instrument of analyzing how the concomitant activation of peptide pathways may occur without the use of exogenous hormones.

The scientific basis of the combination of CJC-1295 and Ipamorelin commences with the scientific discussion of the signaling of peptide based hormone by describing peptide hormone signaling and the significance of the growth hormone signaling. The discussion provides the contextual framework of how this peptide mix should be reviewed by first determining the reason why this combination of peptides is present, and the synergistic laws that may arise when these peptides are combined.

II. CJC-1295: SUSTAINED GROWTH HORMONE SIGNALING

CJC-1295 is an artificial peptide-based compound that was designed to help maintain the release of growth hormone (GH) by activating endogenous regulation systems as opposed to the administration of the hormone itself. Structurally, it acts as a liability of growth hormone-releasing hormone (GHRS), a naturally found hypothalamic peptide that stimulates GH to be released by the anterior pituitary gland. CJC-1295 can bind directly to GHRH receptors on pituitary somatotroph cells by mimicking their main regions, triggers intracellular signaling pathways, which stimulate the synthesis and release of GH (Chang et al., 2022). One unique fact about CJC-1295 is that the drug prolongs the GHRH signaling. In contrast to endogenous GHRH, which is fast degraded, CJC-1295 is designed with a longer half-life because it is resistant to enzymatic degradation. This prolonged period of signaling helps in maintaining stimulation of GH release in the pituitary as opposed to short and sporadic stimulation. Consequently, CJC-1295 is actively discussed in the research frameworks as the mechanism of enhancing the production of the growth hormone on a baseline level but adhering to the physiological regulatory processes (Goerlich et al., 2023).

CJC-1295 maintains the feedback processes of GH secretion by acting upstream at the point of activation of pituitary receptors. This upstream stimulation separates the peptide based signaling methods and direct hormone administration which avoids hypothalamic regulation by the pituitary. Studies investigating growth hormone secretagogue receptor interactions also highlight the need to promote specificity of receptors during the regulation of sustained hormone release mechanisms (Danila et al., 2022). Also, the identification and tracking of peptide-based agents on the analytical and regulatory research point out their unique biochemical characteristics and prolonged activity relative to endogenous hormones (Flores et al., 2024). CJC-1295 is overall poised as a peptide to promote the sustained and regulated growth hormone signaling through the reinforcement of the naturally occurring GHRH-stimulated pathways instead of the acute or uncontrolled hormone spikes.

Figure 1: CJC-1295 supports prolonged stimulation of growth hormone release through GHRH pathways https://www.puretestedpeptides.com/product/cjc-1295-ipamorelin-5-5-mg-peptide-blend

III. IPAMORELIN: SELECTIVE GROWTH HORMONE PULSE ACTIVATION

Ipamorelin is an artificial growth hormone releasing hormone geared towards beginning the secretion of endogenous growth hormone (GH) by a receptor-specific interaction mechanism. In contrast to peptides which impact more or less overall endocrine systems, Ipamorelin acts mainly by activating the growth hormone secretagogue receptor 1a (GHSR-1a), which is also known as the ghrelin receptor. This receptor-mediated process enables Ipamorelin to cause GH release on the hypothalamic level including the level of hypothalamic pituitary axis and a high level of signaling specificity (Lu et al., 2024). Through this route, Ipamorelin causes discrete and rapid GH pulses that match more closely with the patterns of physiological secretion as opposed to continuous and excessive hormone elevation. One such characteristic of Ipamorelin is that it is selective. Animal and analytical models of experimental studies show that Ipamorelin selectively enhances the release of GH and induces downstream signaling through small amounts of non-target hormonal systems (Gouda & Ganesh, 2024). This selectivity contrasts with previous growth hormone secretagogues which were usually accompanied by simultaneous cortisol or prolactin. This diminished activity with both stress and lactation-related hormones has led to the Ipamorelin being of interest in research contexts that seek to carefully modulate GH instead of stimulating the endocrine system in general (Králik et al., 2026). The pulsatile high-frequency release of GH linked with the Ipamorelin is of specific importance particularly on a regulatory level. Growth hormone is secreted in brief bursts during the day and peptides with this pattern are more physiologically consistent than pharmacological agents that encourage constant exposure to the hormone. Investigative articles analyzing small peptide drugs also point to the similarity of Ipamorelin as a separate compound predictable in terms of signaling behavior, which confirms the use of Ipamorelin as a precision-oriented research peptide (Liu et al., 2025). Further, the research on ghrelin receptors agonists shows that Ipamorelin is able to retain its GH-stimulating effect without causing significant off-target effects even in comparison with structurally related substances (Lu et al., 2024). In general, Ipamorelin can be described by the fact that it induces rapid and controlled GH pulses with the help of selective activation of ghrelin receptors. The specificity of its action and limited communication with either cortisol or prolactin are the reasons why it can be classified as a very specific instrument to study pulsatile growth hormone dynamics, free of long-term signaling plans (Guo et al., 2025).

Table 1: Key Characteristics of Ipamorelin Signaling

Feature	Description
Primary receptor	Growth hormone secretagogue receptor (GHSR-1a)
GH release pattern	Rapid, pulsatile secretion
Hormonal selectivity	High specificity for GH
Cortisol interaction	Minimal
Prolactin interaction	Minimal

Figure 2: Ipamorelin promotes rapid growth hormone release via selective ghrelin receptor activation. https://www.puretestedpeptides.com/product/cjc-1295-ipamorelin-5-5-mg-peptide-blend

© JAN 2026 | IRE Journals | Volume 9 Issue 7 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I7-1714043

IV. MECHANISM OF ACTION: DUAL-PATHWAY SYNERGY

The rationale of the combined use of CJC-1295 and Ipamorelin is dual-pathway approach, which focuses on two different receptor systems but converts to one physiological result: increased endogenous GH release. This method takes advantage of the presence of complementary mechanisms acting in parallel in the hypothalamicpituitary axis instead of increasing the strength of a single signaling pathway. CJC-1295 activates growth hormone-releasing hormone (GHRH) receptors at the pituitary level, which facilitates a long-term signalling environment that keeps GH levels maintained at a baseline. Conversely, Ipamorelin stimulates growth hormone secretagogue receptor (GHSR-1a), which advances isolated and swift GH pulses. When these pathways are concomitantly activated, the response is more coordinated, broader and more physiologically aligned than when they are stimulated by either pathway. This sustained plus pulsatile signaling dynamic resembles closely the natural GH secretion rhythm of the body which is based on a mixture of supportive underlying baseline as well as episodic release peaks. Growth hormone does not occur in a constant form but has a circadian and ultradian rhythm which is intermittent pulses overlaid on a controlled background activity. The combination of CJC-1295 and Ipamorelin, by re-creating this combination pattern of endogenous signaling with the selective activation of ghrelin receptors, is more faithfully recapitulated by single-pathway methods. This equilibrium is the core of the scientific explanation of the blended peptides formulations that include the CJC-1295 + Ipamorelin 5 mg + 5 mg peptide blend that is researchable and educatable at, https://www.puretestedpeptides.com/product/cjc-1295-ipamorelin-5-5-mg-peptide-blend/. Another benefit of this type of dual-pathway synergy is that there is no overstimulation of a particular receptor site. When one signaling mechanism is depended upon, it may cause the risk to raise the desensitization of the receptor or the disproportionate hormonal responses. The blend is able to assist in efficient GH signaling by spreading stimulation between the two regulatory inputs, and it is also capable of maintaining the integrity of the upstream feedback controls. This systemic process underscores the reason why the joint administration of CJC-1295 and Ipamorelin is frequently examined as a more organized and balanced approach to the research of growth hormone regulation, instead of an additive or complementary one.

Table 2: Comparison of Dual-Pathway Growth Hormone Stimulation

Component	Primary receptor	Signaling pattern	Contribution to synergy
CJC-1295	GHRH receptor (pituitary)	Sustained baseline signaling	Maintains prolonged GH support
Ipamorelin	GHSR-1a (ghrelin receptor)	Rapid, pulsatile release	Mimics natural GH peaks
Combined effect	Dual receptors	Sustained + pulsatile	Physiologically aligned GH rhythm

V. FUNCTIONAL OUTCOMES OF SYNERGISTIC GROWTH HORMONE STIMULATION

The joint stimulation of the release of growth hormone (GH) by two regulatory pathways leads to a variety of biological effects that characterize the key role of the hormone in maintaining and adapting the system. With appropriate support of GH signaling, which maintains sustained and physiologically timed pulses, downstream mechanisms of tissue maintenance, metabolism and cell renewal can occur in their regular regulatory relationships. These effects can be explained as functional effects of hormone homeostatic signaling and not performance-enhancing effects per se. Among the biological impacts of controlled GH activity, the ability to repair and keep tissues is one of the main. Growth hormone aids in protein synthesis, support of connective tissues, and cell turnover, especially in tissues that are either exposed to mechanical or metabolic stresses. Dual-pathway stimulation promotes processes associated with recovery in the absence of interference with upstream feedback. It is particularly applicable in the

context of research on the effects of the controlled signaling of hormones on long-term tissue resilience.

There is another major result of the coordinated GH stimulation, which is metabolic efficiency. Growth hormone is involved in lipid metabolism and glucose metabolism and affects the process through which the energy substances are mobilised and used. It has been reported that balanced GH signaling method is linked with enhanced metabolic control by aiding in lipolytic action with glucose levels remaining constant. Notably, the effects are determined by the time and pattern of hormone release highlighting the importance of physiologically timed stimulation and not the constant exposure.Another very important aspect of GH-related biology is sleep-related growth hormone activity. GH peaks that are endogenous are usually the biggest ones during the deep sleep phase, which associates hormone release with circadian and restorative activities. Reinforcing the association between sleep quality and hormonal regulation and aiding the understanding of sleep as a behavioral-endocrine interaction, a set of GH dynamics in support of this natural timing could be valuable to study sleep and endocrine interactions.Growth hormone modulates repair and renewal at the cellular level regulating expression of genes, cell proliferation as well as intracellular signaling pathways. Regulated GH stimulation assists these processes in normal cellular homeostasis, and it is significant that equilibrium endocrine input is valuable in maintaining physiological functioning in the long run.

Figure 3: Enhanced growth hormone activity supports recovery and metabolic balance. https://www.puretestedpeptides.com/product/cjc-1295-ipamorelin-5-5-mg-peptide-blend

VI. ADVANTAGES OF A COMBINED PEPTIDE FORMULATION

Combined peptide formulation has strategic benefits that transcend on the actions of separate compounds, especially in the research where hormone regulation is the object of study. A blended strategy permits concurrent operation of complementary mechanisms via signaling by a single pathway rather than focusing on it, enabling more efficient signaling. The formulation is able to contribute a more balanced endocrine response by sharing regulatory input among different, but converging, pathways, and reduces the intensity of stimulation required at a single receptor site. This compensatory effectiveness is one of the reasons why peptide mixtures with coordinated instead of independent signaling should be developed. The second significant benefit of a combined formulation is that it has fewer requirements of high exposure to one peptide. In cases where biologically meaningful effects can only be obtained when the concentration of the signaling agent is increased or function is prolonged when monosignaling is employed. A blend facilitates the relative independence of any individual component, where each peptide is able to provide a particular regulatory activity. This distributed design allows to maintain the

receptor sensitivity and upstream feedback mechanisms and has controlled signaling.

Patterns of growth hormone stimulation more closely matched with physiological rhythms are also better promoted by blended peptide formulations. The secretion of growth hormone is naturally dynamic and it is regulated by a balance between baseline regulation and episodic release. This dynamic pattern is enabled by a combined formulation of simultaneous use of multiple regulatory inputs to minimize the chances of artificial or exaggerated signalling profiles. This phase correspondence with endogenous rhythms is useful in particular where hormone-related processes are being studied in conditions which attempt to model normal physiology. Practically, the combination of peptide preparations simplifies the application of research since complementary agents are combined into one preparation that is standardized. This minimises variability due to independent handling, dosing or time of separate peptides thus enhancing consistency across experiments. Consequently, blended formulations provide a precise and efficient platform to investigate the growth hormone related signaling without losing the clarity, control, and reproducibility of research design.

VII. FORMULATION QUALITY AND RESEARCH CONSIDERATIONS

The design of a peptide mixture is very important in terms of reliability, reproducibility and interpretability in research and education fields. CJC-1295 and ipamorelin formulation are given as a 5 mg precision blend + 5 mg precision blend, which is an equal and standardized composition that is meant to enable controlled study of growth hormone signaling. This fixed ratio allows simplification of experiment design as it offers consistency in all studies, minimizing variability which may occur due to independent preparation or due to imbalanced ratios of components. Accuracy in mixing means every peptide will be proportionate to the overall formulation that will be useful in carrying out research.The purity and consistency are major considerations in research of peptides. Fluctuations in peptide purity may affect receptor bindings, signal transduction and the results of analysis. A development that has taken the focus of purity also ensures that the biological responses are predictable and enable the results to be interpreted. Regular control of manufacturing and quality ensures that there is batch-to-batch consistency that is critical in the case of peptides when the experiment follows a comparative analysis or other repeated protocols. Analytically, it has been found that high-purity formulations are also detectable and characterized better in the laboratory, enabling a sound methodological assessment. The positioning of the formulation in a manner that it can be used in research and education is also important. Such a label positions the peptide blend as a scientific discovery instrument and not a therapeutic one, hence its application fits within the laboratory research, mechanistic research, and learning settings. This positioning will help to ensure that regulatory and ethical standards are observed and that the scope of intended use is understood. The formulation contributes to responsible management and proper contextualization of the research in academic or experimental settings due to its attention to the alignment of research. The CJC-1295 + Ipamorelin 5 mg + 5 mg peptide blend can be found at the following website as a reference and specifications of the product:https://www.puretestedpeptides.com/product/cjc-1295-ipamorelin-5-5-mg-peptide-blend/

Table 3: Formulation Attributes and Research Relevance

Attribute	Description	Research relevance
Peptide composition	CJC-1295 (5 mg) + Ipamorelin (5 mg)	Balanced and standardized blend
Formulation approach	Precision blending	Reduces variability across studies
Purity focus	Emphasis on consistency and quality	Supports reproducible results
Intended use	Research and educational applications	Ensures compliant positioning

CONCLUSION

The entire concept of combination of CJC-1295 and Ipamorelin is based on a sound scientific foundation of coordinated regulation of GH rather than a unilateral stimulation of GH. This combination demonstrates how to maintain a balance between two regulatory mechanisms that ultimately drive GH out and make things physiologically healthy. It is simply a matter of addressing sustained and pulsatile aspects of the hormone regulation in that hypothalamus-pituitary circuit. The synergy phenomenon pokes into the joint action of the peptides. Instead of simply activating a single receptor, the mix disperses its signal on to two receptors yet still cooperating, maintaining the efficiency and retaining the feedback measures of the body. Not a big additive effect it is, then, but an actual, real-world interaction of a number of regulatory inputs in normal conditions. Consider the entire package as a research and classroom learning precision pairing on the current dynamics of GH. The design will be used to assist any person to replicate the results, maintain regulatory concerns transparent, and remain faithful to the basics of endocrinology. Concentrating on mechanism, balance and mediated signals, this combination is a textbook exemplification of an approach to research which is research-oriented, based on science and contacting the tweaks of hormones in a scientist-like manner.

REFERENCES

[1] Chang, C. W., Sung, Y. W., Hsueh, Y. W., Chen, Y. Y., Ho, M., Hsu, H. C., ... & Chang, H. M. (2022). Growth hormone in fertility and infertility: Mechanisms of action and clinical applications. *Frontiers in endocrinology*, *13*, 1040503. https://doi.org/10.3389/fendo.2022.1040503

[2] Chen, Y., Xu, Z., Liu, T., Li, D., Tian, X., Zheng, R., ... & Sun, F. (2024). Application of deep brain stimulation and transcranial magnetic stimulation in stroke neurorestoration: A review. *Journal of Neurorestoratology*, *12*(2), 100120.https://doi.org/10.1016/j.jnrt.2024.100120

[3] Danila, G. M., Puiu, M., Zamfir, L. G., & Bala, C. (2022). Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor. *Talanta*, *237*, 122905.https://doi.org/10.1016/j.talanta.2021.122905

[4] Flores, L., Hargrave, S., Clifford, A., Alarcio, G., & Moeller, B. C. (2024). Detection of doping peptides and basic drugs in equine urine using liquid chromatography–mass spectrometry. *Drug Testing and Analysis*, *16*(4), 406-419. https://doi.org/10.1002/dta.3544

[5] Goerlich, C. E., Griffith, B., Hanna, P., Hong, S. N., Ayares, D., Singh, A. K., & Mohiuddin, M. M. (2023). The growth of xenotransplanted hearts can be reduced with growth hormone receptor knockout pig donors. *The Journal of thoracic and cardiovascular surgery*, *165*(2), e69-e81. https://doi.org/10.1016/j.jtcvs.2021.07.051

[6] Gouda, M., & Ganesh, C. B. (2024). The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. *Animal Reproduction Science*, *268*, 107550. https://doi.org/10.1016/j.anireprosci.2024.107550

[7] Guo, L., Zhang, X., Liu, Y., Zhang, A., Song, W., Li, L., ... & Pang, Q. (2025). Salt-alkali-tolerant growth-promoting Streptomyces sp. Jrh8-9 enhances alfalfa growth and resilience under saline-alkali stress through integrated modulation of photosynthesis, antioxidant defense, and hormone signaling. *Microbiological Research*, *296*, 128158. https://doi.org/10.1016/j.micres.2025.128158

[8] Králík, F., Kvíčalová, A., Salaďáková, A., Kuchař, M., & Setnička, V. (2026). Growth Hormone–Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions. *Chirality*, *38*(2), e70083. https://doi.org/10.1002/chir.70083

[9] Liu, Y., Ma, C., Dong, T., Yan, K., He, G., Wang, Z., ... & Chang, W. (2025). Elucidating important factors and corresponding method optimization for sensitive detection of small peptide drugs in human urine by solid-phase extraction and UPLC-HRMS: The influence of MS scan modes, protein precipitants, and

ammonium formate. *Drug Testing and Analysis*, *17*(4), 457-469. https://doi.org/10.1002/dta.3746

[10] Lu, Z., Ngan, M. P., Liu, J. Y., Yang, L., Tu, L., Chan, S. W., ... & Rudd, J. A. (2024). The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. *Physiology & Behavior*, *284*, 114644. https://doi.org/10.1016/j.physbeh.2024.114644

[11] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Rick Hatch, G. F., ... & Weber, A. E. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. *The American Journal of Sports Medicine*, *54*(1), 223-229.https://doi.org/10.1177/03635465251357593

[12] Mousikou, M., Kyriakou, A., & Skordis, N. (2023). Stress and growth in children and adolescents. *Hormone research in paediatrics*, *96*(1), 25-33. https://doi.org/10.1159/000521074

[13] Sahoo, D. K., & Chainy, G. B. (2023). Hormone-linked redox status and its modulation by antioxidants. In *Vitamins and hormones* (Vol. 121, pp. 197-246). Academic Press. https://doi.org/10.1016/bs.vh.2022.10.007

[14] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. *The Journal of Clinical Endocrinology & Metabolism*, *91*(3), 799-805.https://doi.org/10.1210/jc.2005-1536

[15] Uçaktürk, E., & Nemutlu, E. (2025). Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 117207.https://doi.org/10.1016/j.jpba.2025.117207

[16] Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. *Substance Use & Misuse*, *51*(1), 73-84.https://doi.org/10.3109/10826084.2015.1082595

[17] Xu, D., Wang, M., Huang, R., Stoddart, J. F., & Wang, Y. (2025). A Dual-Pathway Responsive Mechanophore for Intelligent Luminescent Polymer Materials. *Journal of the American Chemical Society*, *147*(5), 4450-4458.https://doi.org/10.1021/jacs.4c15655

[18] Xu, W., Qiao, L., Wang, Z., Qian, Y., Li, L., Sun, Q., & Li, C. (2023). Dual-pathway STING activation and chemodynamic therapy for improved anti-tumor therapy. *Chemical Engineering Journal*, *474*, 145702.https://doi.org/10.1016/j.cej.2023.145702

[19] Yan, C., Zhu, X., Chen, B., Guan, H., Gu, K., & Liu, H. (2025). Protein/peptide-polyphenol Interactions: Molecular mechanisms, functional synergy, and emerging applications. *Trends in Food Science & Technology*, 105194. https://doi.org/10.1016/j.tifs.2025.105194

[20] Yu, Y., Cui, Z., Zhou, T., Wang, Y., Chen, P., Wang, S., ... & Liu, Y. (2025). Umami peptide synergy unveiled: A comprehensive study from molecular simulation to practical validation of sensing strategy. *Biosensors and Bioelectronics*, *278*, 117331. https://doi.org/10.1016/j.bios.2025.117331